Fundraising FoxMicrobiome Therapeutics
New Orleans, US · Delaware LLC · 3 employees on LinkedIn · 6 known investors
Find your way into Microbiome Therapeutics
Sign up to see every warm intro you have to Microbiome Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Microbiome Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
MH
Mark HeimanCSO2010–2018Dr. Mark Heiman earned a Ph.D. in Physiology from LSU School of Medicine and completed postdoctoral training in neuroendocrinology at Indiana University School of Medicine before working at Tulane University School of Medicine, where he co-invented the drug Lanreotide for treating pituitary adenomas. At Eli Lilly Research Labs starting in 1987, he led metabolic physiology research on obesity and energy regulation, including foundational work on leptin and ghrelin signaling, before retiring in 2009 as Chief Scientific Officer of Obesity Research and co-founding Microbiome Therapeutics.
DP
Dale PfostNamed on SEC filing
Board
DM
Don MarvinBoard director
RM
Richard MontgomeryBoard director
RB
Ross BarrettBoard director
JE
John ElstrottBoard director
PC
Paul CordesBoard director
Investors · 6
Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M
How we know: Sofinnova Ventures's portfolio page · Not right? Tell us
DCVC (Data Collective)reportedPalo Alto · $5M – $25M
How we know: funding news · Not right? Tell us
FemHealth VenturesreportedShort Hills
How we know: funding news · Not right? Tell us
Pangaea Ventures Us Inc.reportedVancouver · $500K – $1.5M
How we know: funding news · Not right? Tell us
Also in the syndicate · 1
MIG Fonds
Funding
SEC filings, press & company announcements$743.4K disclosed across 1 of 3 rounds · 2014–2026
- Undisclosed amountSeries AMay 2026Source ↗
- Undisclosed amountSeries AApr 2026
Bayern Kapital, MIG Fonds
Source ↗
▶$743.4KraisedJun 2015 · 27 investors · Other Health CareRule 506(b)
▶$743.4KraisedJun 2015 · 27 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Dale PfostExecutive Officer, Director, Promoter
- Don MarvinDirector
- Mark HeimanExecutive Officer
- Richard MontgomeryDirector
- Ross BarrettDirector
- John ElstrottDirector, Promoter
- Paul CordesDirector
- Offering amount
- $1.8M
- Amount sold
- $743.4K
- First sale
- Oct 2014
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Microbiome Therapeutics's investors?
- Microbiome Therapeutics's investors include Sofinnova Ventures, Bayern Kapital, DCVC (Data Collective), FemHealth Ventures, Pangaea Ventures Us Inc..
- How much funding has Microbiome Therapeutics raised?
- Microbiome Therapeutics has disclosed $743.4K raised across 1 of its 3 known rounds.
- Where is Microbiome Therapeutics headquartered?
- Microbiome Therapeutics is headquartered in New Orleans, US.